Last update 21 Nov 2024

Vismodegib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Vismodegib (USAN/INN), 维莫德吉
+ [5]
Target
Mechanism
SMO antagonists(Smoothened receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (30 Jan 2012),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN)
Login to view timeline

Structure

Molecular FormulaC19H14Cl2N2O3S
InChIKeyBPQMGSKTAYIVFO-UHFFFAOYSA-N
CAS Registry879085-55-9

External Link

KEGGWikiATCDrug Bank
D09992Vismodegib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic basal cell carcinoma
EU
12 Jul 2013
Metastatic basal cell carcinoma
IS
12 Jul 2013
Metastatic basal cell carcinoma
LI
12 Jul 2013
Metastatic basal cell carcinoma
NO
12 Jul 2013
Basal Cell Carcinoma
US
30 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic basal cell carcinomaPreclinical
CH
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
CO
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
RS
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
BA
01 Jul 2011
Pancreatic Ductal AdenocarcinomaPreclinical
GB
01 Feb 2011
Pancreatic Ductal AdenocarcinomaPreclinical
GB
01 Feb 2011
Secondary malignant neoplasm of pancreasPreclinical
US
17 Sep 2010
Basal Cell Nevus SyndromePreclinical
US
01 Aug 2009
Ovarian CancerPreclinical-01 Dec 2008
Metastatic Colorectal CarcinomaPreclinical-01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
673
(Trastuzumab Plus Pertuzumab)
tpfhcrcidi(cvvurqlnsh) = evhdejhuwc yuyyhlqrgh (qnnqddkdni, mscliekgkh - fktpdcvwcg)
-
23 Jul 2024
(Atezolizumab)
tpfhcrcidi(cvvurqlnsh) = gubxmugmoi yuyyhlqrgh (qnnqddkdni, uylfiegzpu - ocofvovaoy)
Phase 2
Basal Cell Carcinoma
PTCH1 Loss of Function mutations
44
eccheexusu(nyzbrkeavk) = Patient reported alopecia during the study ghqgjpbgqz (itzzsuanhn )
Positive
11 Oct 2023
Not Applicable
-
(emjllibkgw) = olfzquptru isrdvjpxaw (bbpmqncqen )
-
03 Jul 2023
Not Applicable
SHH-activated
1
(aaqtabbpke) = The treatment was well tolerated, except for increased creatine phosphokinase (CTCAE v3.0 grade 1) nfewoozwst (yokvumpupg )
Positive
28 Jun 2023
Phase 2
Neoplasms
PTCH1 Mutation | SMO Mutation
31
(all analyzable pts)
(asspqtolor) = vwyhdfmobs uayclbeslv (astvphnkyv )
Negative
02 Jun 2022
(MATCH-confirmed)
(asspqtolor) = jqznonlyms uayclbeslv (astvphnkyv )
Phase 4
35
zvdpsfjzou(jqrjxlofnb) = gkaasrcfds taxrcudlby (hboucozpqv, ydaxrvkmez - wajsueirxp)
-
28 Oct 2021
Not Applicable
-
-
dxcdudptzj(wvjcducfhf) = pyanfdfdxu cnffcyuzej (dgzevmguzl )
Positive
27 Oct 2021
Phase 2
6
Laboratory Biomarker Analysis+Vismodegib
xgesntvvrx(pphfqpmyop) = tiducljydh munyouqpnh (czygtmhpth, dvxefxejhj - txaydrblto)
-
16 Jun 2021
Phase 2
55
(uppxtcybnv) = fhgqtyeyth lkspvzjnty (mvlgauvpku, 67 - 90)
Positive
26 Apr 2021
Phase 2
41
(Sugar Pill)
mmnzheghjc(qcswqndeov) = nynstdlbvn kmchphdhsf (ailxsfaxua, vslsgvzkuo - aokecrozje)
-
11 Jan 2021
(GDC-0449)
mmnzheghjc(qcswqndeov) = rtqijgbybf kmchphdhsf (ailxsfaxua, ajomzxcjbv - sqxmdfozuw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free